Adc Therapeutics Sa Stock Fundamentals
| ADCT Stock | USD 4.34 0.10 2.25% |
ADC Therapeutics SA fundamentals help investors to digest information that contributes to ADC Therapeutics' financial success or failures. It also enables traders to predict the movement of ADC Stock. The fundamental analysis module provides a way to measure ADC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ADC Therapeutics stock.
At this time, ADC Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 55.9 M in 2024, whereas Interest Income is likely to drop slightly above 5 M in 2024. ADC | Select Account or Indicator |
ADC Therapeutics SA Company Shares Outstanding Analysis
ADC Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current ADC Therapeutics Shares Outstanding | 82.53 M |
Most of ADC Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ADC Therapeutics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ADC Shares Outstanding Historical Pattern
Today, most investors in ADC Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ADC Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ADC Therapeutics shares outstanding as a starting point in their analysis.
ADC Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
ADC Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, ADC Therapeutics SA has 82.53 M of shares currently outstending. This is 54.29% lower than that of the Communications Equipment sector and 22.76% lower than that of the Information Technology industry. The shares outstanding for all United States stocks is 85.57% higher than that of the company.
ADC Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ADC Therapeutics's current stock value. Our valuation model uses many indicators to compare ADC Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ADC Therapeutics competition to find correlations between indicators driving ADC Therapeutics's intrinsic value. More Info.ADC Therapeutics SA is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies . At this time, ADC Therapeutics' Return On Equity is comparatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value ADC Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ADC Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ADC Therapeutics' earnings, one of the primary drivers of an investment's value.ADC Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADC Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADC Therapeutics could also be used in its relative valuation, which is a method of valuing ADC Therapeutics by comparing valuation metrics of similar companies.ADC Therapeutics is currently under evaluation in shares outstanding category among related companies.
ADC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ADC Therapeutics from analyzing ADC Therapeutics' financial statements. These drivers represent accounts that assess ADC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADC Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.0B | 2.1B | 1.6B | 300.1M | 135.6M | 128.9M | |
| Enterprise Value | 1.9B | 1.7B | 1.2B | 91.0M | (18.6M) | (17.6M) |
ADC Fundamentals
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (2.22) % | ||||
| Current Valuation | 507.53 M | ||||
| Shares Outstanding | 82.53 M | ||||
| Shares Owned By Insiders | 24.07 % | ||||
| Shares Owned By Institutions | 41.10 % | ||||
| Number Of Shares Shorted | 888.13 K | ||||
| Price To Earning | 19.80 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 5.21 X | ||||
| Revenue | 69.56 M | ||||
| Gross Profit | 35.1 M | ||||
| EBITDA | (145.78 M) | ||||
| Net Income | (240.05 M) | ||||
| Cash And Equivalents | 376.78 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 124.38 M | ||||
| Debt To Equity | 2.75 % | ||||
| Current Ratio | 5.76 X | ||||
| Book Value Per Share | (1.80) X | ||||
| Cash Flow From Operations | (118.69 M) | ||||
| Short Ratio | 1.81 X | ||||
| Earnings Per Share | (2.94) X | ||||
| Price To Earnings To Growth | 0.74 X | ||||
| Target Price | 10.2 | ||||
| Number Of Employees | 273 | ||||
| Beta | 1.74 | ||||
| Market Capitalization | 358.18 M | ||||
| Total Asset | 354.78 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 268.62 M | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 288.7 M | ||||
| Net Asset | 354.78 M |
About ADC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ADC Therapeutics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 4.3 M | 4.5 M | |
| Total Revenue | 80 M | 50.1 M | |
| Cost Of Revenue | 2.3 M | 2.2 M | |
| Stock Based Compensation To Revenue | 0.19 | 0.18 | |
| Sales General And Administrative To Revenue | 1.05 | 1.00 | |
| Research And Ddevelopement To Revenue | 1.83 | 1.74 | |
| Capex To Revenue | (0.05) | (0.05) | |
| Revenue Per Share | 0.85 | 0.54 | |
| Ebit Per Revenue | (2.39) | (2.51) |
Pair Trading with ADC Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ADC Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ADC Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against ADC Stock
| 0.78 | CSCO | Cisco Systems Fiscal Quarter End 30th of April 2024 | PairCorr |
| 0.56 | AAPL | Apple Inc Earnings Call This Week | PairCorr |
| 0.55 | LPL | LG Display Financial Report 20th of May 2024 | PairCorr |
| 0.43 | ZEPP | Zepp Health Corp | PairCorr |
The ability to find closely correlated positions to ADC Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ADC Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ADC Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ADC Therapeutics SA to buy it.
The correlation of ADC Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ADC Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ADC Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ADC Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ADC Therapeutics Piotroski F Score and ADC Therapeutics Altman Z Score analysis. Note that the ADC Therapeutics information on this page should be used as a complementary analysis to other ADC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for ADC Stock analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is ADC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADC Therapeutics. If investors know ADC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Revenue Per Share 0.851 | Quarterly Revenue Growth (0.76) | Return On Assets (0.25) | Return On Equity (7.06) |
The market value of ADC Therapeutics is measured differently than its book value, which is the value of ADC that is recorded on the company's balance sheet. Investors also form their own opinion of ADC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ADC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADC Therapeutics' market value can be influenced by many factors that don't directly affect ADC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.